Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease (MagiCal-CKD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02542319|
Recruitment Status : Unknown
Verified June 2018 by Nordsjaellands Hospital.
Recruitment status was: Recruiting
First Posted : September 7, 2015
Last Update Posted : June 6, 2018
|Condition or disease||Intervention/treatment||Phase|
|Chronic Kidney Disease Vascular Calcification Uremic Osteodystrophy||Dietary Supplement: Mablet 360 mg Dietary Supplement: Placebo||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||250 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||The Effect of Oral Magnesium Supplementation on Vascular Calcification in Chronic Kidney Disease - A Randomized Clinical Trial|
|Study Start Date :||November 2015|
|Estimated Primary Completion Date :||February 2020|
|Estimated Study Completion Date :||May 2020|
Oral Magnesium Hydroxide (Mablet 360 mg) twice daily for 12 months.
Dietary Supplement: Mablet 360 mg
Placebo Comparator: Placebo
Matching placebo tablets twice daily for 12 months.
Dietary Supplement: Placebo
- Coronary Artery Calcification (CAC) score [ Time Frame: 12 months ]Agatston score assessed by CT scan.
- Bone Mineral Density (BMD) [ Time Frame: 12 months ]BMD assessed by quantitative CT.
- Pulse Wave Velocity [ Time Frame: 12 months. ]
- Serum Calcification Propensity [ Time Frame: 12 months. ]Serum calcification propensity assessed by T50 analysis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02542319
|Contact: Iain B Bressendorff, MDemail@example.com|
|Contact: Lisbet Brandi, MD, DMScfirstname.lastname@example.org|
|Herlev, Denmark, 2730|
|Contact: Ditte Hansen, MD PhD +4538682056 email@example.com|
|Hillerød, Denmark, 3400|
|Contact: Iain B Bressendorff, MD +4524277139 firstname.lastname@example.org|
|Contact: Lisbet Brandi, MD DSMc +4548295993 email@example.com|
|Lørenskog, Norway, 1478|
|Contact: My Svensson, MD PhD +4791569601 firstname.lastname@example.org|
|Principal Investigator:||Iain B Bressendorff, MD||North Zealand Hospital|